Evidence map›Paper›PMID 30376560›Full record

ArticlePloS one2018

Hormonal contraceptive use and risk of pancreatic cancer-A cohort study among premenopausal women.

Sedrah Arif Butt, Øjvind Lidegaardi, Charlotte Skovlund, Philip C Hannaford, Lisa Iversen, Shona Fielding, Lina Steinrud Mørch

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Pancreatic Cancer: A Review of Risk Factors.Life (Basel, Switzerland) · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Sedrah Arif ButtCopenhagen University Hospital, The Juliane Marie Centre, Department of Gynecology, Copenhagen, Denmark.ORCID 0000-0002-0275-7440
Øjvind LidegaardiCopenhagen University Hospital, The Juliane Marie Centre, Department of Gynecology, Copenhagen, Denmark.
Charlotte SkovlundCopenhagen University Hospital, The Juliane Marie Centre, Department of Gynecology, Copenhagen, Denmark.
Philip C HannafordAcademic Primary Care, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom.
Lisa IversenAcademic Primary Care, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom.
Shona FieldingMedical Statistics Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom.
Lina Steinrud MørchCopenhagen University Hospital, The Juliane Marie Centre, Department of Gynecology, Copenhagen, Denmark.
Copenhagen University Hospital · DKUniversity of Aberdeen · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

importanceThe association between the use of hormonal contraceptive and pancreatic cancer among premenopausal women has until now been unclear. This is the first study to investigate the risk of pancreatic cancer in pre-menopausal women.

objectiveTo determine whether hormonal contraception increases the risk of developing pancreatic cancer in pre-menopausal women.

designA nationwide prospective cohort study followed all women in Denmark in the age range of 15-49 years without previous cancer or venous thrombosis from 1995 to 2014. The Danish National Prescription Registry provided individually updated exposure information on use of hormonal contraception. The Danish Cancer Registry provided cancer diagnoses, and the Danish National Patient Register containing clinical diagnoses and surgical codes at discharge from public and private hospitals.

settingPopulation-based cohort study.

participantsAll women living in Denmark aged 15-49 years at January 1st, 1995, and those subsequently reaching age 15 years up to December 31st, 2014 were eligible for the study.

resultsAmong 1.9 million women who were followed on average for 11.4 years, 235 pancreatic cancers occurred. Compared to never users, ever users of any type of hormonal contraception had a relative risk (RR) of pancreatic cancer of 0.90 (95% confidence interval (CI) 0.68-1.19). No overall association between duration of hormonal contraceptive use and pancreatic cancer risk was found. Neither was long-term use of hormonal contraception associated with pancreas cancer, RR 0.83 (95% CI 0.47-1.50). The risk did not vary between users of combined and progestogen-only products. All models were adjusted for age, completed or ongoing education, polycystic ovary syndrome, endometriosis and among parous women; parity, age at first birth, smoking and body mass index. CONCLUSIONS AND RELEVANCE: Compared to never users the risk of pancreatic cancer is not significantly higher among current and recent users of contemporary hormonal contraception and does not vary between users of combined and progestogen-only products. In conclusion, our study suggests no risk of pancreatic cancer with use of any type of hormonal contraception.

Indexed as

AdolescentAdultBody Mass IndexCohort StudiesContraceptives, Oral, HormonalDenmarkEndometriosisFemaleHumansMiddle AgedPancreatic NeoplasmsPolycystic Ovary SyndromePremenopauseProspective StudiesRegistriesRiskContraceptives, Oral, Hormonal

Identifiers

PMID30376560
PMCPMC6207333
OpenAlexW2899443872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.